• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Prolight Diagnostics

18.68 SEK+1.52 %24.7, 17.23
Less than 1K followers

PRLD

NGM Growth Market

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.52 %
+41.73 %
+27.25 %
-5.56 %
+4.36 %
-23.13 %
-85.97 %
-85.81 %
-52.54 %

Prolight Diagnostics develops point-of-care (POC) systems. These are small mobile instruments with disposable test cards that can perform In-Vitro Diagnostic (IVD) tests from a drop of blood. The POC system can contribute to faster and more accurate diagnoses of acute conditions. The company's launch product will be a highly sensitive measurement of troponin to be able to determine and exclude heart attacks.

Read more
Market cap
225M SEK
Turnover
96.45K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Forum discussions
And then for a slightly more up-to-date situational analysis: the company has turned out to be a disappointment in my case. Schedules are slipping and there is still no information about the clinical trial. I would estimate that new share issues will be arranged by May at the latest...
1/29/2026, 1:44 PM
2
Did anyone attend the shareholders’ meeting or the investor presentation held at the end of the month? I would be very interested to know what the management said about future schedule targets. I find the company’s communication regarding the schedules rather odd. Pre-validation ...
7/3/2025, 7:26 AM
2
Tänään tuli ensimmäiset tulokset (25/120) tuoreen veren tutkimuksista. Kurssi pomppasi aluksi tarjoten hyvän myyntipaikan. Kaikkiin tutkimusuutisiin liittyviin pomppuihin kannattaa myydä niin paljon kuin likviditeettiä riittää, koska tuloksien odotetaan olevan hyviä, jolloin tutkimuksen...
6/16/2025, 2:34 PM
by Gubrick
2
NOTE: This post has been sitting in draft mode since August, and I only noticed it now. Some time has passed, so the information might be outdated. Psyros is about to receive a new Europe-wide patent. I see this patent as quite significant; in general, the European Patent Office ...
1/29/2026, 1:34 PM
1
It probably wouldn’t make it to the main list, no. Here is the schedule included in the investor presentation held at the end of last month on 24.6: Pre-clinical validation studies are marked for H1 2025. Although it seems that St Thomas’ studies will continue for a while longer....
7/3/2025, 11:07 PM
1
Excellent result. H1 2026 is at least entirely time to try and seek a deal. It wouldn’t even need to cover the entire funding need, because after that, money could be brought in again with good valuation and small dilution.
7/2/2025, 7:28 AM
by Gubrick
1
Yesterday, an article was published with the headline “Prolight finalises instrument design and prepare for pilot manufacturing”. However, the article rather describes that the instrument is still being finalized, consistent with previous press releases. placera.se Prolight slutf...
1/30/2026, 12:13 PM
0
Read more on our forum
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8
2026

Interim report Q2'26

26.11
2026

Interim report Q3'26

Regulatory press release13.07.2026, 07.30

Prolight signs GBP 2.24m development agreement with BRAINBox

Prolight Diagnostics
Press release08.07.2026, 13.10

Prolight receives Notice of Allowance for Psyros® patent in the US

Prolight Diagnostics
Regulatory press release26.05.2026, 16.40

Prolight Diagnostics publishes quarterly report Q1, 2026

Prolight Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release26.05.2026, 16.30

Annual general meeting of Prolight Diagnostics AB (publ) on 26 May 2026

Prolight Diagnostics
Regulatory press release05.05.2026, 15.30

Prolight Diagnostics AB (publ) publishes annual report for 2025

Prolight Diagnostics
Press release29.04.2026, 08.00

Prolight Diagnostics achieves design freeze for Psyros® instrument

Prolight Diagnostics
Press release28.04.2026, 08.00

Prolight secures second patent in Japan for Psyros® technology

Prolight Diagnostics
Regulatory press release21.04.2026, 17.10

NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)

Prolight Diagnostics
Press release14.04.2026, 16.32

Prolight selected as semi-finalist for ADLM 2026 Disruptive Technology Award Competition

Prolight Diagnostics
Press release24.03.2026, 08.15

Prolight Diagnostics publishes investorletter for March 2026

Prolight Diagnostics
Press release24.03.2026, 08.00

Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform

Prolight Diagnostics
Press release09.03.2026, 08.00

Prolight Diagnostics’ POC system Psyros attracted significant attention at the recently concluded international WHX Labs congress

Prolight Diagnostics
Press release03.03.2026, 08.15

Biostock publishes an article after Prolight published its Year-End Report for 2025

Prolight Diagnostics
Regulatory press release26.02.2026, 08.00

Prolight Diagnostics publishes year-end report 2025

Prolight Diagnostics
Press release02.02.2026, 08.30

Biostock publishes an article describing how Prolight scales-up cartridge manufacturing

Prolight Diagnostics
Press release30.01.2026, 08.00

Biostock publishes an article about Prolight finalises instrument design and prepare for pilot manufacturing

Prolight Diagnostics
Press release28.01.2026, 11.55

Prolight Diagnostics publishes investorletter for January 2026

Prolight Diagnostics
Press release18.12.2025, 08.20

Biostock publishes an article about the key milestone toward commercialisation - assay design freeze

Prolight Diagnostics
Press release18.12.2025, 06.57

BioStock: Prolight Diagnostics reaches high-sensitivity troponin assay design freeze – a key milestone for Psyros

Prolight Diagnostics
Press release17.12.2025, 08.00

Prolight Diagnostics achieves assay design freeze for Psyros™ point-of-care cartridge – A key milestone toward commercialisation

Prolight Diagnostics